The following article appeared in the Wall Street Journal this week, Good news for all.
Michael More BigCharts Virtual Stock Exchange FiLife.com WSJ Asia WSJ Europe WSJ Portuguese WSJ Spanish WSJ Chinese WSJ RadioFinancial News Online SEARCH Tuesday, December 8, 2009 As of 3:17 PM EST HealthWelcome, Logout My AccountMy JournalHelpMessage Center ( new) U.S. EditionWSJ.com is available in the following editions and languages: U.S. Asia India China Europe Americas en Español em Português Login/ Register to set your edition .Set my edition .Today's Paper VideoColumnsBlogsTopicsJournal Community Register for FREE Register for FREEThank you for registering. We sent an email to: Please click on the link inside the email to complete your registration Please register to gain free access to WSJ tools. An account already exists for the email address entered. Forgot your username or password? This service is temporary unavailable due to system maintenance. Please try again later. The username entered is already associated with another account. Please enter a different username The email address you have entered is already in use. Please re-enter the email address. First Name Last Name Email (your email address will be your login) Confirm Email Create a Password Confirm Password From time to time, we will send you e-mail announcements on new features and special offers from The Wall Street Journal Online. Create a profile for me in the Journal Community Why Register? Privacy Policy | Terms & Conditions As a registered user of The Wall Street Journal Online, you will be able to: Setup and manage your portfolio Personalize your own news page Receive and manage newsletters Log In Log InLogin Password Log in Your login is either a username or an email address. Keep me logged in. Forgot your password? Close HomeWorldU.S.BusinessMarketsTechPersonal FinanceLife & StyleOpinionCareersReal EstateSmall Business AsiaEuropeEarningsEconomyHealthLawAutosManagementMedia & Marketing More Industries AccountingAdvertisingAirlinesBankingChemicalsComputer HardwareComputer SoftwareConsumer ProductsDefense & AerospaceEnergyBroadcasting & EntertainmentFinancial Services & InsuranceFood & TobaccoHospitalityIndustrial Goods & ServicesMarketing & StrategyMedia AgenciesMetals & MiningPaper & Forest ProductsPharmaceutical & BiotechReal EstateRetailSemiconductorsTransportationUtilitiesColumns & Blogs Dow Jones Reprints: This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers, use the Order Reprints tool at the bottom of any article or visit www.djreprints.com See a sample reprint in PDF format. Order a reprint of this article now DECEMBER 8, 2009, 3:17 P.M. ET.Novartis's Tasigna Beats Gleevec in Trial .ArticleComments (1)more in Health ». EmailPrinter FriendlyShare: facebook ↓ More. .StumbleUponDiggTwitterYahoo! BuzzFarkRedditLinkedIndel.icio.usMySpaceSave This ↓ More. . Text . By JEANNE WHALEN Novartis AG's new leukemia drug, Tasigna, performed better than the company's blockbuster Gleevec leukemia treatment in initial results of a clinical trial, a finding that could help Novartis start positioning the newer drug to replace Gleevec. Gleevec is the company's second biggest selling drug, with revenue of $3.7 billion last year. But it will lose patent protection and face competition from low-cost generic copies in 2015. If enough doctors decide that Tasigna is the better treatment, Novartis could hold onto leukemia-drug sales longer because Tasigna's patent won't expire till later. The Novartis-financed study tested Tasigna against Gleevec in 846 patients who were newly diagnosed with a form of blood cancer called chronic myeloid leukemia. After a year of treatment, a blood test measuring the presence of the disease showed a major drop in about twice as many of the patients who took Tasigna, according to results of the study presented Tuesday at the American Society of Hematology's annual meeting in New Orleans. In about 80% of patients taking Tasigna and 65% of those taking Gleevec, a chromosome indicating the presence of the disease disappeared from the bone marrow. And more patients who took Gleevec— about 4% compared with less than 1%—progressed to an advanced stage of the disease. Gleevec is known by the generic name imatinib. Tasigna's generic name is nilotinib. "The superior efficacy and favorable tolerability profile of nilotinib compared with imatinib suggests that nilotinib may become the standard of care in newly diagnosed CML patients," the doctors who led the study wrote in an abstract summarizing the results. The study is set to continue for several more years. Gleevec has been on the market since 2001 and is considered one of the great successes of modern cancer treatment. One study showed that about 89% of patients taking the drug were still alive after five years, a remarkable result for cancer treatment. There is little data yet on whether Tasigna actually extends patients' survival, which is the most important outcome of any treatment. Novartis tried to design Tasigna to attack CML even more precisely than Gleevec does. Both drugs work by binding to a pocket in an aberrant enzyme called BCR-ABL that causes white blood cells to grow and divide uncontrollably. Tasigna was designed to occupy that pocket more snugly and shut down the enzyme's activity more fully. Tasigna is already approved for sale in many markets for the treatment of CML patients who are resistant to or intolerant of Gleevec. Novartis said it now plans to ask regulators for permission to sell Tasigna for use in newly diagnosed CML patients. Eric Feldman, a hematologist at New York Presbyterian Hospital who was not involved in the new study, called the data "pretty compelling" and said Tasigna should be "seriously considered" as a treatment for newly diagnosed patients. Richard Stone, a hematologist at Dana-Farber Cancer Center in Boston, called the data "encouraging" but said he might want to see another year or more of data before prescribing Tasigna instead of Gleevec to new patients. Andrew Weiss, a pharmaceutical analyst at Bank Vontobel AG in Zurich, said that because there is so much evidence that Gleevec extends survival—while there is little yet for Tasigna— some doctors might be hesitant to switch to the newer drug. Tasigna "needs to show that it's even better than Gleevec in survival terms," he said. "Do we see that with this data? No. Does the drug have the potential to show that data? Yes." Also, when generic copies of Gleevec become available, they will be much cheaper than the still-patented Tasigna, which can cost more than $40,000 a year. This could give some healthcare payers pause about paying for Tasigna, Mr. Weiss said. Write to Jeanne Whalen at [email protected] Copyright 2009 Dow Jones & Company, Inc. All Rights Reserved This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com -- [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [email protected] For more options, visit this group at http://groups.google.com/group/CMLHope
